While Genentech and Roche have been on the hunt for cancer therapies, they’ve also been investing in new construction.
The company announced on Tuesday that it has opened the doors to its new $250 million manufacturing site for small-batch biologics in South San Francisco.
The site, called the “Clinical Supply Center,” will eventually make Genetech’s experimental drugs, the Roche subsidiary tells
Endpoints News
via email.
The 78,520 square-foot building took the company around two years to build as the company broke ground on the site just before the Covid-19 pandemic kicked off into high gear in February of 2020. The company expects medicine production to start next year, the company added in its email to Endpoints.
According to the company, the facility also plans to use fewer resources in the manufacturing process to reduce the environmental impact of the site.
This opening comes as Genentech has been making several plays earlier in the month. The company recently
shelled out
$80 million in upfront cash to license Kiniksa’s vixarelimab and lead it into new clinical trials. Researchers plan to launch Phase II studies in idiopathic pulmonary fibrosis/interstitial lung disease sometime later this year.
The company, along with Roche, also placed a
$60 million
bet to partner with Jemincare to push forward a new program for prostate cancer.